References
- Cartherics . Peter MacCallum Cancer Centre and Cartherics announce collaboration to develop autologous CAR-T cell therapy for cutaneous T-cell lymphoma(2022). https://cartherics.com/news/peter-maccallum-cancer-centre-and-cartherics-announce-collaboration-to-develop-autologous-car-t-cell-therapy-for-cutaneous-t-cell-lymphoma/
- Cynata Therapeutics . New trial using stem cells to stop kidney transplant rejection(2022). www.cynata.com/news/new-trial-using-stem-cells-to-stop-kidney-transplant-rejection
- ElevateBio . ElevateBio and Affini-T Therapeutics announce partnership to advance Affini-T’s T cell therapy programs targeting core oncogenic drivers(2022). www.elevate.bio/press-releases/elevatebio-and-affini-t-therapeutics-announce-partnership-to-advance-affini-ts-t-cell-therapy-programs-targeting-core-oncogenic-drivers
- bit.bio . bit.bio expands its portfolio with three new human cell products for research and drug discovery in neurodegenerative and neurological diseases(2022). www.bit.bio/news/launch-mapt-gaba
- FUJIFILM . Fujifilm invests $188 million in new cell culture media manufacturing facility(2022). www.fujifilm.com/us/en/news/FISI_North_Carolina
- Biogennix . Biogennix’s DirectCell advanced bone grafting system used in 1000th case(2022). https://biogennix.com/news/directcell-1000th-case/
- ElevateBio . ElevateBio BaseCamp unveils its LentiPeak™ lentiviral vector platform(2022). www.elevate.bio/press-releases/elevatebio-basecamp-unveils-its-lentipeak-lentiviral-vector-platform
- Namocell . Namocell highlighted in Nature Publication for efficient single cell cloning of human pluripotent stem cells(2022). www.namocell.com/namocell-highlighted-in-nature-publication/
- Tristan CA , HongH , JethmalaniYet al. Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail. Nat. Protoc. (2022). https://pubmed.ncbi.nlm.nih.gov/36261632/
- Lineage Cell Therapeutics . Lineage announces launch of Phase IIA study by Genentech of RG6501 (OpRegen®) in patients with geographic atrophy secondary to age-related macular degeneration(2022). https://investor.lineagecell.com/node/22691/pdf
- NCT05626114 . A study to optimize subretinal surgical delivery and to evaluate safety and activity of opregen in participants with geographic atrophy secondary to age-related macular degeneration(2022). https://clinicaltrials.gov/ct2/show/NCT05626114
- Edigene . EdiGene announces completion of last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion dependent β-thalassemia(2022). www.edigene.com/media/119.html
- NCT04925206 . A safety and efficacy study evaluating ET-01 in subjects with transfusion dependent β-thalassaemia (ET-01)(2022). https://clinicaltrials.gov/ct2/show/NCT04925206
- Editas Medicine . Editas Medicine announces clinical data demonstrating proof of concept of EDIT-101 from Phase I/II BRILLIANCE trial(2022). https://ir.editasmedicine.com/node/11341/pdf
- NCT03872479 . Single ascending dose study in participants with LCA10(2022). https://clinicaltrials.gov/ct2/show/NCT03872479
- Priothera . Priothera – Positive mocravimod Phase IB clinical data published in transplantation and cellular therapy(2022). https://priothera.com/priothera-positive-mocravimod-phase-1b-clinical-data-published-in-transplantation-and-cellular-therapy/
- Dertschnig S , GergelyP , FinkeJet al. Mocravimod, a selective sphingosine-1-phosphate receptor modulator, in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant. Cell Ther.29(1), 41.e1–41.e9 (2022).
- NCT05429632 . Phase IIb placebo-controlled study of mocravimod as adjunctive and maintenance treatment in AML patients in allo-HSCT (MO-TRANS)(2022). https://clinicaltrials.gov/ct2/show/NCT05429632
- Aleta Biotherapeutics . Aleta Biotherapeutics receives innovation passport designation for Biologic CAR T-cell therapy engager ALETA-001(2022). http://www.aletabio.com/wp-content/uploads/2022/11/Aleta-Bio-Receives-IP-Designation-FINAL.pdf
- AgeX Therapeutics . AgeX Therapeutics receives extension of time to attain compliance with stock exchange continued listing requirements(2022). https://investors.agexinc.com/news/news-details/2022/AgeX-Therapeutics-Receives-Extension-of-Time-to-Attain-Compliance-With-Stock-Exchange-Continued-Listing-Requirements/default.aspx
- Hemanext . Hemanext announces close of series B equity funding round(2022). https://hemanext.com/hemanext-announces-close-of-series-b-equity-funding-round/
- Novadip Biosciences . Novadip Biosciences raises additional EUR 40 million bringing total company funding to EUR 88 million(2022). https://novadip.com/press-releases/novadip-biosciences-raises-additional-eur-40-million-bringing-total-company-funding-to-eur-88-million/